Trial Profile

A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of FR104, a Novel Antagonist Pegylated Anti-CD28 Fab' Antibody Fragment in De Novo Renal Transplant Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Nov 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
05 Jun 2024 According to Veloxis Pharmaceuticals, Inc media release, company in collaboration with Nantes University Hospital Present Positive analysis at the American Transplant Congress 2024
05 Jun 2024 According to Veloxis Pharmaceuticals, Inc media release, Pr. Gilles Blancho is principal Investigator of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com